UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care

Posted by Jenna Widdison
On November 20, 2017

REDWOOD CITY, Calif. – December 20, 2017 – Pulmonx® Corp. today announced that the UK's National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now...

Posted by Jenna Widdison
On September 8, 2017

REDWOOD CITY, Calif. – September 8, 2017 – Pulmonx® Corp. today announced the publication of positive six-month results from TRANSFORM, a multicenter, multinational, randomized clinical trial (RCT) of the Zephyr® Endobronchial Valve (EBV®) in the American Journal of Respiratory and Critical Care...

Posted by Jenna Widdison
On May 23, 2017

Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without...

UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care

New Study Demonstrates Zephyr Endobronchial Valves Significantly Improve Breathing, Mobility and Quality of Life for Emphysema Patients

New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients without Collateral Ventilation

Pulmonx Australia Suite 5, Level 6 65 York Street Sydney, NSW 2000 Australia

1300 785 666

info@pulmonx.com.au